Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the six analysts that are currently covering the firm, MarketBeat reports. Three research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $66.75.
RIGL has been the subject of a number of research analyst reports. Cantor Fitzgerald upped their price target on Rigel Pharmaceuticals from $43.00 to $47.00 and gave the company a “neutral” rating in a report on Friday, November 6th. Weiss Ratings lowered shares of Rigel Pharmaceuticals from a “buy (b)” rating to a “buy (b-)” rating in a research note on Monday, November 9th. Piper Sandler reaffirmed a “neutral” rating and set a $49.00 price objective (up from $40.00) on shares of Rigel Pharmaceuticals in a report on Monday, August 17th. Citigroup upped their target price on Rigel Pharmaceuticals from $83.00 to $86.00 and gave the company a “buy” rating in a research report on Monday, November 9th. Finally, Zacks Research raised Rigel Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Thursday.
Check Out Our Latest Stock Report on RIGL
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of RIGL. BlackRock Inc. acquired a new stake in Rigel Pharmaceuticals during the 2nd quarter worth approximately $75,886,000. Assenagon Asset Management S.A. acquired a new position in Rigel Pharmaceuticals in the 3rd quarter valued at $25,793,000. Bank of America Corp DE purchased a new position in Rigel Pharmaceuticals during the 2nd quarter worth $4,832,000. Globeflex Capital L P acquired a new stake in shares of Rigel Pharmaceuticals in the 2nd quarter worth $4,408,000. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Rigel Pharmaceuticals in the second quarter valued at about $4,233,000. 66.23% of the stock is owned by hedge funds and other institutional investors.
Rigel Pharmaceuticals Stock Performance
Shares of RIGL opened at $44.46 on Monday. Rigel Pharmaceuticals has a 1 year low of $24.95 and a 1 year high of $52.60. The stock has a market capitalization of $837.18 million, a PE ratio of 2.87 and a beta of 1.28. The stock has a 50-day simple moving average of $47.44 and a 200-day simple moving average of $37.64.
Rigel Pharmaceuticals (NASDAQ:RIGL – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The biotechnology company reported $0.65 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.27). The firm had revenue of $80.89 million during the quarter, compared to analysts’ expectations of $80.00 million. Rigel Pharmaceuticals had a net margin of 106.59% and a return on equity of 14.89%. Analysts predict that Rigel Pharmaceuticals will post 2.97 EPS for the current year.
About Rigel Pharmaceuticals
Rigel Pharmaceuticals, Inc. is a biotechnology company that discovers, develops and commercializes medicines for people with serious hematologic disorders and cancers. Founded in 1996 and based in South San Francisco, California, the company has focused on treatments that target biological pathways involved in disease. Rigel’s marketed products include Tavalisse (fostamatinib), an oral treatment for adults with chronic immune thrombocytopenia who have had an insufficient response to prior treatment, and Rezlidhia (olutasidenib), an oral therapy for certain adults with relapsed or refractory acute myeloid leukemia containing an IDH1 mutation.
Featured Stories
- Five stocks we like better than Rigel Pharmaceuticals
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Rigel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rigel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
